SILO — Silo Pharma, Inc.

Is SILO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Silo Pharma, Inc. (SILO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.46. The rating moved from Neutral to Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Silo Pharma, Inc. (SILO) is a small‑cap specialty pharma/biotech with limited public financial detail; near‑term performance will be driven by pipeline milestones, liquidity/events that de‑risk programs, and any partnership or non‑dilutive financing. Broader market risk‑off sentiment and a cooling IPO window are headwinds for micro‑cap healthcare names, while successful late‑stage clinical outcomes in the specialty pharma space remain a clear upside catalyst. Policy shifts around drug pricing and Medicare program design add structural uncertainty to future revenue and access assumptions. Given informational opacity and elevated execution risk, expect volatile trading that is catalyst‑dependent with a material risk of dilution absent clear near‑term funding or partnering.

Key factors

  • Silo Pharma, Inc. (SILO) is a micro‑cap specialty/pharma issuer with limited publicly available financial disclosures and apparent dependence on pipeline progress and external financing.
  • Recent market risk‑off tone and cooling of the IPO window reduce demand for small healthcare equities and increase volatility/liquidity risk.
  • Sector tailwinds for successful late‑stage specialty biologics can materially re‑rate companies with positive clinical readouts or commercial evidence.
  • Policy pressure from Medicare drug‑price negotiations and shifting payer dynamics increases uncertainty around pricing, access and commercial returns for specialty therapies.
  • Potential near‑term catalysts include clinical trial readouts, partnerships or licensing deals that could provide validation or non‑dilutive funding.
  • Absence of social sentiment and EDGAR comparatives in the provided data increases informational opacity for short‑term investors.

Risks

  • Limited cash runway and high probability of equity dilution to fund operations, common with micro‑cap biotech/specialty pharma issuers.
  • Clinical and regulatory failure risk if the company is dependent on early‑stage programs; trial setbacks could materially impair valuation.
  • Payer/pricing pressure from Medicare negotiation (IRA) and aggressive Medicare Advantage plan designs that can reduce realized prices or access.
  • Competitive risk from larger incumbents and next‑generation therapies (including GLP‑1/amylin combos where relevant to therapeutic area).
  • Liquidity and market‑depth risk: low trading volumes can magnify price moves during broader risk‑off periods and make exits difficult.
  • Operational and supply‑chain disruptions from geopolitics or manufacturing constraints that could delay development or commercialization timelines.

See today's live rating, score and targets

Members see the live hourly rating for SILO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.